CapsoVision, Inc.
CVHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CapsoVision, Inc. focuses on Medical Devices services and products. CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. With a market capitalization of $335.3M, it sits in small-cap territory. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Market Cap
$335.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.12
EPS (Fwd)
—
ROE
-185.1%
ROA
-88.1%
Cash
$17.9M
Total Debt
$788,000
Free CF
-$13.2M
52W Change
47.5%
Annual Financials
Cash vs Debt
CapsoVision, Inc. holds $17.9M in cash against $788K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$13.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -185.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $9.8M (2023) to $13.6M (2025), reflecting a 39% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CapsoVision, Inc. and its sector.